JCR Pharmaceuticals Co., Ltd.
Financial Summary for the Six Months Ended March 2027 (Interim) [Japanese GAAP] (Consolidated)
For the six months ended March 2027, consolidated net sales were 19,974 million yen, down 6.5% year-over-year. Operating loss was 3,504 million yen, ordinary loss was 3,798 million yen, and net loss attributable to owners of the parent was 3,867 million yen. R&D expenses increased by 30.6%. A dividend of 10 yen was paid at the end of the second quarter; full-year forecast is 20 yen. There is no change to the full-year outlook for the fiscal year ending March 2027 as previously announced.
Key Figures
- Net Sales: 19,974 million yen
- Operating Loss: -3,504 million yen
- Ordinary Loss: -3,798 million yen
AI要約
Overview of Results
Net sales for the interim period were 19,974 million yen, a 6.5% decrease year-over-year. The primary reasons were a decline in contract fee income and reduced revenue from the Grow project. A significant increase in research and development expenses led to an operating loss. Ordinary loss also widened, resulting in an interim net loss of 3,867 million yen. Segment information is omitted because the pharmaceutical business constitutes a single reportable segment.
Future Capital Policy and Financial Position
Cash and cash equivalents have decreased, total assets and liabilities have increased, and the equity ratio declined by 7.0 percentage points. A commitment line agreement totaling 49,500 million yen has been arranged as a backup; of this, 26,500 million yen is planned to be allocated for financing a new formulation manufacturing plant. Cash flow was negative from operating activities, significant outflows for investing activities, and a notable net increase in borrowings in financing activities.
JCR Pharmaceuticals Co., Ltd.
Company overview · Stock price · Financial data · All IR
